Pamrevlumab

Status
Phase 3
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. 

Study Purpose

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis.

Find a Clinical Trial

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >